NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Xencor, Inc. XNCR
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$125.6M
▲ 13.7% vs FY2024
EPS · FY25
$-1.24
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-14.0%
Net margin · FY25
-73.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 125.6M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 73 cents on every revenue dollar this year.
Per share
USD -1.24
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-14.0%
Return on equity, FY2025
ROE
Operating margin-141.4%
Net margin-73.2%
Return on assets-10.1%
Each USD of equity lost 14 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+0.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−8.6%
+0.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+24.2%
Change, 10 years+77.2%
The share count grew 24% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 875.5M
total assets, end of FY2025
Total assetsUSD 875.5M
EquityUSD 635.6M
CashUSD 54.1M
Gross debtUSD 119.7M
Net debtUSD 65.7M
Current ratio6.25×
Net debt stands at 10% of equity.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.1
0.1
0.2
0.2
0.3
0.1
0.2
0.0
0.0
0.1
·
·
·
·
Operating income $B
−0.2
−0.2
−0.1
−0.1
0.0
−0.1
0.0
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.2
−0.1
−0.1
0.1
−0.1
0.0
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
·
·
·
·
Net income $B
−0.1
−0.2
−0.1
−0.1
0.1
−0.1
0.0
−0.1
−0.0
0.0
−0.0
−0.0
−0.1
−0.0
EPS, diluted $
−1.24
−3.58
−2.20
−0.93
1.37
−1.21
0.46
−1.31
−0.82
1.07
−0.45
−0.52
−3.85
−118.86
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−14.0
−34.7
−19.2
−7.6
12.7
−11.9
4.8
−16.8
−11.8
18.0
−15.9
−24.7
·
·
Shares out B
0.07
0.07
0.06
0.06
0.06
0.06
0.06
0.06
0.05
0.05
0.04
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed